Article Figures & Tables
Figures
- Fig. 1.
Deletion of RBP-J within renin cells of Bl6 and SV mice leads to B-cell leukemia and MPD, respectively. (A) Representative flow cytometry plots performed on the bone marrow of control and mutant mice from the SV (left panel) and Bl6 (right panel) background. Conditional deletion of RBP-J within renin cells of SV mice results in decreased number of CD19+B220+ B cells and an increase in CD11b+Gr1− and CD11b+Gr1+ myeloid cells. Conversely, conditional deletion of RBP-J within renin cells of Bl6 mice results in an aberrant population of CD19+B220dim leukemic B cells and a decrease in myeloid cells. (B) Mutant animals from the Bl6 background have increased spleen weight, liver weight and white blood cell count, as well as decreased hemoglobin, compared with mutant animals from the SV background. Further, mutant SV animals with two copies of Cre recombinase have increased spleen weight, increased white blood cell count and decreased hemoglobin compared with mutant SV animals with one copy of Cre recombinase. There was a trend towards worse disease in mutant Bl6 animals with two copies of Cre recombinase compared with Bl6 animals with one copy of Cre recombinase, although this was not statistically significant. *P<0.05, **P<0.01 and ***P<0.001, Mann–Whitney U-test. The sample size for each group is shown. (C) Animals with two copies of Cre recombinase (RBP-Jfl/fl;Ren1dCre/Cre) have a higher incidence of B-cell leukemia compared with mice with only one copy of Cre recombinase (RBP-Jfl/fl;Ren1dCre/+) for both the SV and Bl6 background. Mutant animals from the Bl6 background predominantly develop B-cell leukemia, whereas mutant animals from the SV background have a higher incidence of MPD (P<0.001, Fisher's exact test). The sample size for each group is shown. (D) In both SV and Bl6 mice, survival decreases in mutant animals with two copies of Cre recombinase (RBP-Jfl/fl;Ren1dCre/Cre) compared with those with only one copy (RBP-Jfl/fl;Ren1dCre/+). The sample size for each group is shown.
- Fig. 2.
Deletion of RBP-J within renin cells of SV mice leads to dermatitis. (A-C) Mutant animals from the SV background develop hair loss over their back (A) and cystic nodules on their snouts (B) and tails (C). (D-F) With age, hair loss (D) progresses to ulceration and hyperkeratinization (E,F). Pictures are of the same mouse at day of life 57 (D), day of life 107 (E) and day of life 155 (F). (G-I) Hematoxylin and Eosin staining demonstrates thickened epidermis and dermis, as well as large cysts and inflammatory infiltrates, in mutant animals (H,I) compared with control animals (G). Scale bars: 200 µm.
- Fig. 3.
Dermatitis in SV mice is due to deletion of RBP-J within progenitor cells of the skin and the MPD is a secondary, reactive process. (A) Renin lineage (GFP+) cells are present in the skin of RBP-Jfl/+;Ren1dCre/+(SV);mTmG control mice (left). The nodular and cystic skin lesions of RBP-Jfl/fl;Ren1dCre/+(SV);mTmG mutant mice are partially GFP positive, signifying the presence of Cre recombinase and thus deletion of RBP-J within skin lesion cells (right). Scale bars: 200 μm. (B) PCR was performed on genomic DNA from bone marrow cells from control animals, animals with B-cell leukemia and animals with dermatitis/MPD, using primers designed to detect wild-type RBP-J alleles, floxed RBP-J alleles and RBP-J alleles that have undergone Cre-mediated deletion. The bone marrow cells from animals with MPD show predominantly floxed RBP-J alleles, but not deletion alleles, confirming that the myeloid cells have not undergone deletion of RBP-J. (C) Flow cytometry on bone marrow cells from mutant Bl6 animals shows a large population of CD19+B220dim leukemia cells, which are largely GFP positive (left panel). Conversely, the bone marrow from mutant SV mice has an increased population of CD11b+Gr1+ myeloid cells, which are RFP positive (right panel), and thus have not undergone Cre-mediated recombination of RBP-J.
- Fig. 4.
Bl6 mice have more renin lineage cells within hematopoietic tissues compared with SV mice. (A) Bl6 mice have a trend towards more renin lineage cells (marked by GFP) in the spleen compared with SV mice (P=0.057, Mann–Whitney U-test). There is a non-significant trend towards more renin lineage cells in the bone marrow as well (P=0.076, Mann–Whitney U-test). The sample size for each group is shown. (B) There are more renin lineage cells (GFP+) in the peripheral blood of Bl6 mice compared with SV mice throughout life. (C) Immunofluorescent images of renin lineage (GFP+) cells in the spleen and liver of newborn SV mice compared with newborn Bl6 mice. Scale bars: 100 µm.
- Fig. 5.
Renin-expressing cells are a susceptible population for malignant transformation. (A) Comparison of the expression pattern of different B-cell Cre recombinase transgenes – Mb1-Cre, CD19-Cre and renin-Cre – within the bone marrow and spleen by flow cytometry. Within the bone marrow and spleen, Mb1Cre;mTmG mice have the highest number of B cells that express GFP, followed by CD19Cre;mTmG and Ren1dCre;mTmG. *P<0.05 and **P<0.01, Kruskal–Wallis test. The sample size for each group is shown. (B) Cre-mediated GFP expression in the spleens of Mb1Cre;mTmG, CD19Cre;mTmG and Ren1dCre;mTmG mice. Scale bars: 200 µm. (C) Conditional deletion of RBP-J within renin-expressing cells leads to the development of B-cell leukemia and early death. However, conditional deletion of RBP-J within Mb1-expressing or CD19-expressing cells does not lead to B-cell leukemia. At advanced ages, 20% of RBP-Jdel/fl;Mb1Cre/+ mice and 50% of RBP-Jdel/fl;CD19Cre/+ mice developed abdominal tumors, leading to abdominal distension and death. The sample size for each group is shown. (D) Conditional deletion of RBP-J within renin-expressing cells, but not Mb1-expressing or CD19-expressing cells, resulted in elevated spleen weight, liver weight and white blood cell count and decreased hemoglobin compared with littermate control mice. *P<0.05 and **P<0.01, Mann–Whitney U-test. The sample size for each group is shown. (E) Representative tumor from RBP-Jdel/fl;CD19Cre/+ mice (leftmost). By flow cytometry analysis, abdominal tumors were positive for CD5 but negative for B-cell and myeloid markers. Further, the tumors were RFP+ and thus not due directly to deletion of RBP-J. FSC, forward scatter; SSC, side scatter.
Keywords
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Subject collections
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Professor Elizabeth Patton appointed as DMM’s next Editor-in-Chief
We are pleased to announce that The Company of Biologists directors have appointed Professor Elizabeth Patton as DMM's new Editor-in-Chief. As Paresh Vyas writes in his Editorial, Liz ‘brings vitality and a passion for the remit of DMM, and is deeply embedded in the community.’
Did you know DMM Conference Travel Grants can be used for online meetings?
With travel restrictions still in place, we want to continue supporting early-career researchers in their careers. DMM’s Conference Travel Grants can now be used to attend virtual and online scientific meetings, workshops, conferences and training courses.
The current application round closes on 8 February 2021 – find out more.
Identification of MYOM2 as a candidate gene in hypertrophic cardiomyopathy and Tetralogy of Fallot, and its functional evaluation in the Drosophila heart
Research from Silke Sperling and colleagues uses Drosophila to identify MYOM2 as a candidate gene in congenital heart malformations in this issue’s Editor’s choice.
C. elegans as a disease model
A new Research article from Doyle et al., models spinal muscular atrophy in C. elegans to show that that targeting therapies to muscle cells is more effective than neuronal delivery. Find more research using C. elegans as a disease model in our latest subject collection.
Call for papers – The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is now welcoming submissions until 1 April 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway. Find out more about the issue and how to submit your manuscript.
Interview – Kim Landry-Truchon and Nicolas Houde
In an interview, first authors Kim Landry-Truchon and Nicolas Houde discuss their mouse model of the early stages of pleuropulmonary blastoma, reflecting on the implications of their work and the future of their field.